Positive top-line results for Xtampza ER abuse deterrent potential
US specialty pharma company Collegium Pharmaceutical (Nasdaq: COLL) saw its shares rise 3.9% to $17.48 after its announced positive top-line from a clinical trial evaluating the abuse potential of its Xtampza ER (oxycodone extended-release capsules) compared to chewed Xtampza ER, and crushed immediate-release oxycodone in solution in non-dependent, recreational drug abusers.
The study met its primary and secondary endpoints of lower “Drug Liking” and “Take Drug Again.”
The results demonstrated that intact and chewed Xtampza ER (fed or fasted) had statistically significantly lower peak "Drug Liking" (Emax) when compared with crushed immediate-release oxycodone. Furthermore, Xtampza ER when taken chewed was bioequivalent to taking it intact as determined by Cmax and AUC.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze